S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
This Stock Could Go Up 66% or More. (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
This Stock Could Go Up 66% or More. (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
Experts: NVIDIA Now "Too Big to Succeed" (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
This Stock Could Go Up 66% or More. (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
This Stock Could Go Up 66% or More. (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
Experts: NVIDIA Now "Too Big to Succeed" (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
This Stock Could Go Up 66% or More. (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
This Stock Could Go Up 66% or More. (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
Experts: NVIDIA Now "Too Big to Succeed" (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
This Stock Could Go Up 66% or More. (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
This Stock Could Go Up 66% or More. (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Asian shares fall over China worries, Seoul trading closed for a holiday
Experts: NVIDIA Now "Too Big to Succeed" (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy

Apellis Pharmaceuticals (APLS) Stock Forecast, Price & News

$38.84
-4.34 (-10.05%)
(As of 09/27/2023 ET)
Compare
Today's Range
$35.06
$43.03
50-Day Range
$23.65
$48.53
52-Week Range
$19.83
$94.75
Volume
9.21 million shs
Average Volume
2.82 million shs
Market Capitalization
$4.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.13

Apellis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
70.3% Upside
$66.13 Price Target
Short Interest
Bearish
11.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.39mentions of Apellis Pharmaceuticals in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$10.57 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.89) to ($2.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

144th out of 976 stocks

Pharmaceutical Preparations Industry

49th out of 454 stocks


APLS stock logo

About Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

APLS Price History

APLS Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4%
A Bio-Tech Stock That Has Been Growing Like Crazy!
Recent News for This One Bio-Tech Has Us All Getting Excited. Sign Up today And Learn More
Robert W. Baird Remains a Buy on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Up to $43.31
See More Headlines
Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Company Calendar

Last Earnings
7/31/2023
Today
9/27/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLS
Fax
N/A
Employees
767
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$66.13
High Stock Price Forecast
$141.00
Low Stock Price Forecast
$29.00
Forecasted Upside/Downside
+66.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
15 Analysts

Profitability

Net Income
$-652,170,000.00
Net Margins
-356.02%
Pretax Margin
-356.37%

Debt

Sales & Book Value

Annual Sales
$75.42 million
Book Value
$1.54 per share

Miscellaneous

Free Float
108,907,000
Market Cap
$4.68 billion
Optionable
Not Optionable
Beta
1.08

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Cedric Francois M.D. (Age 51)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $1.2M
  • Dr. Pascal Deschatelets Ph.D. (Age 53)
    Co-Founder & Chief Scientific Officer
    Comp: $688.05k
  • Mr. Alec  Machiels J.D.Mr. Alec Machiels J.D. (Age 50)
    MBA, Co-Founder & Director
    Comp: $72.5k
  • Mr. Timothy E. SullivanMr. Timothy E. Sullivan (Age 52)
    CFO & Treasurer
    Comp: $716.41k
  • Mr. David O. Watson Esq.Mr. David O. Watson Esq. (Age 50)
    J.D., Gen. Counsel
    Comp: $675.35k
  • Mr. Adam J. TownsendMr. Adam J. Townsend (Age 46)
    Chief Commercial Officer
    Comp: $701.61k
  • Ms. Nur  NicholsonMs. Nur Nicholson (Age 54)
    Chief Technical Operations Officer
  • Mr. James G. Chopas CPA (Age 57)
    VP, Corp. Controller & Chief Accounting Officer
  • Ms. Meredith Kaya
    Sr. VP, Investor Relations & Strategic Fin.
  • Ms. Karen  LewisMs. Karen Lewis (Age 51)
    Chief People Officer













APLS Stock - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APLS shares.
View APLS analyst ratings
or view top-rated stocks.

What is Apellis Pharmaceuticals' stock price forecast for 2023?

15 equities research analysts have issued 1 year price objectives for Apellis Pharmaceuticals' stock. Their APLS share price forecasts range from $29.00 to $141.00. On average, they anticipate the company's share price to reach $66.13 in the next year. This suggests a possible upside of 66.4% from the stock's current price.
View analysts price targets for APLS
or view top-rated stocks among Wall Street analysts.

How have APLS shares performed in 2023?

Apellis Pharmaceuticals' stock was trading at $51.71 at the beginning of the year. Since then, APLS shares have decreased by 23.1% and is now trading at $39.75.
View the best growth stocks for 2023 here
.

Are investors shorting Apellis Pharmaceuticals?

Apellis Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 13,610,000 shares, an increase of 10.6% from the August 31st total of 12,310,000 shares. Based on an average trading volume of 4,730,000 shares, the days-to-cover ratio is currently 2.9 days.
View Apellis Pharmaceuticals' Short Interest
.

When is Apellis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our APLS earnings forecast
.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) issued its quarterly earnings data on Monday, July, 31st. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.35) by $0.33. The company had revenue of $95 million for the quarter, compared to analyst estimates of $70.38 million. Apellis Pharmaceuticals had a negative net margin of 356.02% and a negative trailing twelve-month return on equity of 212.82%. The business's quarterly revenue was up 482.8% on a year-over-year basis. During the same period last year, the firm earned ($1.46) earnings per share.

What ETFs hold Apellis Pharmaceuticals' stock?
What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.88%), State Street Corp (1.94%), Jennison Associates LLC (1.67%), Geode Capital Management LLC (1.27%), Point72 Asset Management L.P. (1.05%) and Artal Group S.A. (0.89%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan, Victoria L Brown and Victoria L Brown.
View institutional ownership trends
.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $39.75.

How much money does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $4.68 billion and generates $75.42 million in revenue each year. The company earns $-652,170,000.00 in net income (profit) each year or ($5.83) on an earnings per share basis.

How many employees does Apellis Pharmaceuticals have?

The company employs 767 workers across the globe.

Does Apellis Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.
Read More
How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com.

This page (NASDAQ:APLS) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -